Millennium Management’s Tvardi Therapeutics TVRD Stock Holding History

Millennium Management’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,436	Closed	-$1.12M	–	7226
2021 Q1	$1.12M	Buy	+1,436	New	+$983K	﹤0.01%	4108
2018 Q3	–	Sell	-3,472	Closed	-$2.39M	–	4342
2018 Q2	$2.39M	Buy	+3,472	New	+$1.76M	﹤0.01%	2278
2018 Q1	–	Sell	-4,167	Closed	-$1.84M	–	4162
2017 Q4	$1.84M	Buy	+4,167	New	+$1.9M	﹤0.01%	2336
2017 Q3	–	Sell	-1,397	Closed	-$774K	–	3931
2017 Q2	$774K	Buy	+1,397	New	+$886K	﹤0.01%	2582
2015 Q3	–	Sell	-889	Closed	-$389K	–	3793
2015 Q2	$389K	Buy	+889	New	+$344K	﹤0.01%	2759

Other funds holding TVRD

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Millennium Management's TVRD Position: Q2 2025 in Review

Millennium Management sold out of Tvardi Therapeutics (TVRD) in Q2 2025, closing a stake of 5,807 shares — an estimated $88.3K sold.

Millennium Management first reported a position in TVRD in Q4 2014 and held it in 33 quarters. The position peaked at $13.2M in Q4 2015. 56 funds tracked by Wall St. Rank hold TVRD as of Q2 2025.

Millennium Management reported no remaining Tvardi Therapeutics position as of Q2 2025 after selling out during the quarter.
Millennium Management sold 5,807 Tvardi Therapeutics shares in Q2 2025, an estimated $88.3K.
Millennium Management first reported a position in Tvardi Therapeutics in Q4 2014 and held it in 33 quarters.
Millennium Management's Tvardi Therapeutics position peaked at $13.2M in Q4 2015.
56 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2025.

Based on Millennium Management's 13F filing for Q2 2025, filed 14 Aug 2025.